Weight loss drug could protect brain function in chronic illness
NCT ID NCT06171152
Summary
This study is testing whether a weight loss medication called liraglutide (Saxenda) affects brain health markers in people with multiple sclerosis, long COVID, or leukemia in remission who also have obesity and cognitive problems. Researchers will measure changes in a protein called BDNF that's linked to brain function over 21 weeks. This early-phase study involves 30 participants to gather initial information about how this medication might influence brain health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.